GAMMORA, developed by Code Pharma, is a revolutionary HIV treatment that targets and eliminates infected cells while preserving healthy ones. What sets GAMMORA apart from traditional treatments is its ability to go beyond merely suppressing the virus—it’s designed to offer a long-term solution by eradicating infected cells at the source.
In preclinical studies and early human trials, GAMMORA has demonstrated remarkable results in reducing viral loads and improving immune function. This is a huge promise not only in fighting active infections but also in promoting the growth of healthy CD4 cells, which are essential for immune health.
The drug is currently undergoing rigorous testing, including animal models and human clinical trials, to confirm its safety and efficacy. Code Pharma is also focusing on ensuring the treatment is user-friendly, with the goal of making it a practical and sustainable solution for HIV patients. CEO Zyon Ayni has shared that GAMMORA could potentially transform HIV care, as it targets the root cause rather than merely managing the virus.
“We’ve proven that HIV-infected cells can be eliminated,” says Ayni, highlighting the importance of the drug’s success in trials. With ongoing research and future regulatory approval, GAMMORA is on track to redefine the approach to HIV treatment.